natgillin/translations-raw huggingface dataset:
Aripiprazole Mylan Pharma is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over. 
Aripiprazole Mylan Pharma se također koristi u razdoblju do 12 tjedana za liječenje umjerenih do ozbiljnih maničnih epizoda u bolesnika u dobi od 13 godina i starijih.
What is Aripiprazole Mylan Pharma and what is it used for? 
Što je Aripiprazole Mylan Pharma i za što se koristi?
Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine'. 
Aripiprazole Mylan Pharma sadrži djelatnu tvar aripiprazol i "generički je lijek".
The full EPAR and risk management plan summary for Aripiprazole Mylan Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Aripiprazole Mylan Pharma nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Aripiprazole Mylan Pharma pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
What measures are being taken to ensure the safe and effective use of Aripiprazole Mylan Pharma? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Aripiprazole Mylan Pharma?
A risk management plan has been developed to ensure that Aripiprazole Mylan Pharma is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Aripiprazole Mylan Pharma.
What are the benefits and risks of Aripiprazole Mylan Pharma? 
Koje su koristi i rizici od lijeka Aripiprazole Mylan Pharma?
Because Aripiprazole Mylan Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify. 
Budući da je Aripiprazole Mylan Pharma generički lijek, ispitivanja na bolesnicima bila su ograničena na ispitivanja za utvrđivanje da je lijek bioekvivalentan referentnom lijeku Abilify.
It is not intended to provide practical advice on how to use Aripiprazole Mylan Pharma. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Aripiprazole Mylan Pharma.
Other information about Aripiprazole Mylan Pharma 
Ostale informacije o lijeku Aripiprazole Mylan Pharma
The active substance in Aripiprazole Mylan Pharma, aripiprazole, is an antipsychotic medicine. 
Aripiprazol, djelatna tvar u lijeku Aripiprazole Mylan Pharma, je antipsihotik.
Why is Aripiprazole Mylan Pharma approved? 
Zašto je lijek Aripiprazole Mylan Pharma odobren?
Previously known as Aripiprazole Pharmathen. 
Ranije poznat pod imenom Aripiprazole
The European Commission granted a marketing authorisation valid throughout the European Union for Aripiprazole Pharmathen on 30 June 2015. 
Pharmathen na snazi u Europskoj uniji od 30. lipnja 2015.
Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk. 
Stoga je stav CHMP-a da u pogledu lijeka Aripiprazole Mylan Pharma koristi nadmašuju utvrđene rizike.
How is Aripiprazole Mylan Pharma used? 
Kako se koristi Aripiprazole Mylan Pharma?
How does Aripiprazole Mylan Pharma work? 
Kako djeluje Aripiprazole Mylan Pharma?
How has Aripiprazole Mylan Pharma been studied? 
Kako je Aripiprazole Mylan Pharma ispitivan?
Date of first authorisation: 3 October 2011 Date of latest renewal: 9 June 2016 
Datum posljednje obnove odobrenja: 9. lipnja 2016.
It is important that you take Telmisartan Teva Pharma every day until your doctor tells you otherwise. 
Važno je uzimati Telmisartan Teva Pharma svaki dan, dok Vam liječnik ne kaže drugačije.
Do not take a double dose to make up for forgotten individual doses. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
• Amifostine (a protective medicine during radiotherapy for cancer treatment) 
• Amifostin (lijek koji se koristi tijekom radioterapije pri liječenju raka)
You can take Telmisartan Teva Pharma with or without food. 
Možete uzimati Telmisartan Teva Pharma sa ili bez hrane.
Corticosteroïds (systemic route) Reduction of the antihypertensive effect. 
Kortikosteroidi (sistemski put primjene) Smanjenje antihipertenzivnog učinka.
• Baclofen (a muscle relaxant) 
• Baklofen (mišićni relaksans)
If you have the impression that the effect of Telmisartan Teva Pharma is too strong or too weak, talk to your doctor or pharmacist. 
Ako mislite da je učinak Telmisartana Teva Pharma prejak ili preslab, razgovarajte sa svojim liječnikom ili ljekarnikom.
Your doctor will normally advise you to stop taking Telmisartan Teva Pharma before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Telmisartan Teva Pharma. 
Liječnik će Vam obično savjetovati da prestanete uzimati Telmisartan Teva Pharma prije nego ostanete trudni ili čim saznate da ste trudni te će Vam savjetovati uzimanje drugog lijeka umjesto Telmisartana Teva Pharma.
The inhibitory effect is maintained over 24 hours and still measurable up to 48 hours. 
Inhibitorni učinak se održava tijekom 24 sata, a još uvijek se može izmjeriti do
Possible side effects of telmisartan: 
Moguće nuspojave telmisartana:
Your doctor may need to change the dose of these other medicines or take other precautions. 
Liječnik će Vam možda morati promijeniti dozu i/ ili poduzeti druge mjere opreza.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder 
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet:
Eastbourne, East Sussex, BN22 9AG United Kingdom 
Eastbourne, East Sussex, BN22 9AG
CLINICAL PARTICULARS 4.1 Therapeutic indications 
KLINIČKI PODACI 4.1 Terapijske indikacije Hipertenzija
- The active substance is telmisartan. 
- Djelatna tvar je telmisartan.
There are no adequate data from the use of Telmisartan Teva Pharma in pregnant women. 
Ne postoje odgovarajući podaci o primjeni Telmisartana Teva Pharma u trudnica.
The event may be a chance finding or related to a mechanism currently not known (see section 
Taj događaj može biti slučajan ili povezan s trenutno nepoznatim mehanizmom (također vidjeti dio 5.1).
What Telmisartan Teva Pharma is and what it is used for 
Što je Telmisartan Teva Pharma i za što se koristi
In case of surgery or anaesthesia, you should tell your doctor that you are taking Telmisartan Teva Pharma. 
U slučaju kirurškog zahvata ili anestezije, trebate obavijestiti svog liječnika da uzimate Telmisartan
- if you have severe liver problems such as cholestasis or biliary obstruction (problems with the drainage of the bile from the liver and gall bladder) or any other severe liver disease. 
- ako imate teške probleme s jetrom kao što su kolestaza ili bilijarna opstrukcija (problemi s drenažom žuči iz jetre i žučnog mjehura) ili neku drugu tešku bolest jetre.
Elderly No dose adjustment is necessary for elderly patients. 
Nije potrebno prilagođavati dozu u starijih bolesnika.
Telmisartan Teva Pharma contains sorbitol. 
Telmisartan Teva Pharma sadrži sorbitol.
Serious adverse drug reactions include anaphylactic reaction and angioedema which may occur rarely (≥1/10,000 to <1/1,000), and acute renal failure. 
Teške nuspojave obuhvaćaju anafilaktičku reakciju i angioedem koji se mogu rijetko pojaviti (≥1/10 000 i < 1/1000) i akutno zatajenje bubrega.
There is no experience regarding the administration of Telmisartan Teva Pharma in patients with recent kidney transplantation. 
Ne postoji iskustvo u vezi primjene Telmisartana Teva Pharma u bolesnika kojima je nedavno transplantiran bubreg.
Telmisartan Teva Pharma is used to treat essential hypertension (high blood pressure) in adults. 
Telmisartan Teva Pharma se primjenjuje u liječenju esencijalne hipertenzije (visoki krvni tlak) u odraslih osoba.
Telmisartan Teva Pharma is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Telmisartan Teva Pharma se ne preporučuje dojiljama te Vaš liječnik može odabrati drugo liječenje za Vas ako želite dojiti, osobito ako je Vaše dijete novorođenče ili je prerano rođeno.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
- Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
Aluminium-Aluminium peelable perforated unit-dose blisters and aluminium-aluminium perforated unitdose blisters. 
Aluminij-Aluminij perforirani blisteri s odvojivim slojem djeljivi na jedinične doze i aluminij-aluminij perforirani blisteri djeljivi na jedinične doze.
Telmisartan Teva Pharma belongs to a class of medicines known as angiotensin-II receptor antagonists. 
Telmisartan Teva Pharma pripada skupini lijekova poznatih kao antagonisti receptora angiotenzina II.
If you take more Telmisartan Teva Pharma than you should 
Ako uzmete više Telmisartana Teva Pharma nego što ste trebali
Before considering the concomitant use of medicinal products that affect the renin-angiotensinaldosterone system, the benefit risk ratio should be evaluated. 
Prije razmatranja istodobne primjene lijekova koji utječu na sustav renin-angiotenzinaldosteron, potrebno je procijeniti omjer koristi i rizika.
Tel/Tél: +32 3 820 73 73 
Tél/Tel: +32 3 820 73 73
Because no information is available regarding the use of Telmisartan Teva Pharma during breast-feeding, Telmisartan Teva Pharma is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant. 
Budući da ne postoje dostupni podaci o primjeni Telmisartana Teva Pharma tijekom dojenja, primjena Telmisartana Teva Pharma se ne preporučuje i prednost se daje drugim lijekovima s bolje utvrđenim sigurnosnim profilima tijekom dojenja, osobito tijekom razdoblja dojenja novorođenčeta ili nedonoščeta.
See also information under the heading “Do not take Telmisartan Teva Pharma”. 
Vidjeti također informacije pod naslovom “Nemojte uzimati Telmisartan Teva Pharma“.
Telmisartan tablets are for once-daily oral administration and should be taken with liquid, with or without food. 
Način primjene Telmisartan tablete primjenjuju se peroralno jednom dnevno i trebaju se uzimati s tekućinom, sa ili bez hrane.
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskirenom kontrainidirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
HU-4042 Debrecen 
H-4042 Debrecen,
The effect of Telmisartan Teva Pharma may be reduced when you take NSAIDs (non steroidal antiinflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids. 
Učinak Telmisartana Teva Pharma se može smanjiti kada uzimate NSAIL (nesteroidne protupalne lijekove, npr. aspirin ili ibuprofen) ili kortikosteroide.
Telmisartan Teva Pharma is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. 
Telmisartan Teva Pharma se također primjenjuje za smanjivanje kardiovaskularnih događaja (tj. srčanog udara ili moždanog udara) u rizičnih odraslih osoba koji imaju smanjenu ili prekinutu opskrbu krvlju srca ili nogu, ili su imali moždani udar, ili imaju šećernu bolest s visokim rizikom za oštećenje organa.
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13). 
Omjer hazarda za telmisartan u odnosu na ramipril bio je 1,01 (97,5 % CI 0,93 - 1,10, p (neinferiornost) = 0,0019 na granici od 1,13).
Symptomatic hypotension, especially after the first dose of Telmisartan Teva Pharma, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting. 
Simptomatska hipotenzija, osobito nakon prve doze Telmisartana Teva Pharma, može se pojaviti u bolesnika koji imaju depleciju volumena i/ili natrija zbog snažne terapije diureticima, prehrane s ograničenim unosom soli, proljeva ili povraćanja.
This applies especially to the medicines listed below taken at the same time with Telmisartan Teva Pharma. 
Ovo se osobito odnosi na lijekove koji su navedeni u nastavku, a uzimaju se istovremeno s Telmisartanom Teva Pharma:
Telmisartan Teva Pharma is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile. 
Telmisartan Teva Pharma se ne smije davati bolesnicima s kolestazom, bilijarnom opstrukcijom ili teškim oštećenjem jetrene funkcije (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
For reduction of cardiovascular events, the usual dose of Telmisartan Teva Pharma is one 80 mg tablet once a day. 
Za smanjivanje kardiovaskularnih događaja, uobičajena doza Telmisartana Teva Pharma je jedna tableta od 80 mg, jedanput na dan.
The recommended dose of Telmisartan Teva Pharma is one tablet a day. 
Preporučena doza Telmisartana Teva Pharma je jedna tableta dnevno.
Other medicines and Telmisartan Teva Pharma 
Drugi lijekovi i Telmisartan Teva Pharma
When Telmisartan Teva Pharma is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. 
Kada se Telmisartan Teva Pharma primjenjuje u bolesnika s poremećenom funkcijom bubrega, preporučuje se povremeno pratiti vrijednosti kalija i kreatinina u serumu.
very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to 
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000).
Hypotension2, orthostatic hypotension 
2, ortostatska hipotenzija
What Telmisartan Teva Pharma looks like and contents of the pack 
Kako Telmisartan Teva Pharma izgleda i sadržaj pakiranja
Telmisartan Teva Pharma is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Telmisartan Teva Pharma je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3).
Some people feel dizzy or tired when they taking Telmisartan Teva Pharma. 
Neki ljudi osjećaju omaglicu ili umor kada uzimaju Telmisartan Teva Pharma.
Telmisartan Teva Pharma may be less effective in lowering the blood pressure in black patients. 
Telmisartan Teva Pharma može biti manje učinkovita u snižavanju krvnog tlaka u bolesnika crne rase.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. 
Stenoza aortnog i mitralnog zaliska, opstruktivna hipertrofička kardiomiopatija Kao i s ostalim vazodilatatorima, potreban je poseban oprez u bolesnika koji imaju aortalnu ili mitralnu stenozu ili opstruktivnu hipertrofičnu kardiomiopatiju.
Contents of the pack and other information What Telmisartan Teva Pharma contains 
Sadržaj pakiranja i druge informacije Što Telmisartan Teva Pharma sadrži
Telmisartan Teva Pharma may increase the blood pressure lowering effect of other medicines used to treat high blood pressure. 
Telmisartan Teva Pharma može povećati učinak snižavanja krvnog tlaka drugih lijekova koji se primjenjuju u liječenju visokog krvnog tlaka.
Arthralgia, pain in extremetis, tendon pain (tendinitis like symptoms) 
Artralgija, bol u ekstremitetima, bol tetiva (simptomi poput tendinitisa)
Aluminium-Aluminium blisters : pack sizes of 28, 30 tablets 
Aluminij-Aluminij blisteri: veličine pakiranja od 28, 30 tableta.
If you forget to take Telmisartan Teva Pharma 
Ako ste zaboravili uzeti Telmisartan Teva Pharma
• Diuretics (‘water tablets'), especially if taken in high doses together with Telmisartan Teva Pharma, may lead to excessive loss of body water and low blood pressure (hypotension). 
• Diuretici ('tablete za izmokravanje'), osobito ako se uzimaju visoke doze zajedno s Telmisartanom Teva Pharma,mogu dovesti do prekomjernog gubitka vode u tijelu te niskog krvnog tlaka (hipotenzija).
Such conditions should be corrected before the administration of Telmisartan Teva Pharma. 
Takva stanja moraju se korigirati prije primjene Telmisartana Teva Pharma.
Telmisartan Teva Pharma should be used only with caution in patients with mild to moderate hepatic impairment. 
Telmisartan Teva Pharma se treba primjenjivati isključivo s oprezom u bolesnika s blagim do umjerenim oštećenjem jetrene funkcije.
Telmisartan Teva Pharma blocks this effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. 
Telmisartan Teva Pharma blokira učinak angiotenzina II, tako da se krvne žile šire, a krvni tlak snižava.
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. 
Osim ako se produljena terapija antagonistima receptora angiotenzina II ne smatra nužnom, bolesnice koje planiraju trudnoću trebaju prijeći na alternativno antihipertenzivno liječenje s utvrđenim sigurnosnim profilom primjene u trudnoći.
- The other ingredients are microcrystalline cellulose (Avicel PH 102), sodium starch glycolate (Type 
Drugi sastojci su: mikrokristalična celuloza (Avicel PH 102), natrijev škroboglikolat (vrste A),
Carefully peel off the top paper layer 
Pažljivo odlijepite gornji papirnati sloj 3.
Other conditions with stimulation of the renin-angiotensin-aldosterone system In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8). 
U bolesnika čiji vaskularni tonus i funkcija bubrega ovise prvenstveno o djelovanju sustava reninangiotenzin-aldosteron (npr. bolesnici s teškim kongestivnim zatajenjem srca ili osnovnom bolešću bubrega, uključujući stenozu bubrežne arterije) liječenje lijekovima koji utječu na ovaj sustav, kao što je telmisartan, je povezano s akutnom hipotenzijom, hiperazotemijom, oligurijom ili rijetko, akutnim zatajenjem bubrega (vidjeti dio 4.8).
The safety and efficacy of Telmisartan Teva Pharma in children and adolescents aged below 18 years have not been established. 
Sigurnost i djelotvornost Telmisartana Teva Pharma u djece i adolescenata u dobi ispod 18 godina nisu ustanovljene.
Telmisartan Teva Pharma is also provided in aluminium-aluminium blister packs of 28 and 30 tablets. 
Telmisartan Teva Pharma je također dostupan u aluminij-aluminij blisteru u pakiranju od 28 ili 30
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as Telmisartan Teva Pharma. 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Prilikom upravljanja vozilima ili strojevima, povremeno može doći do pojave omaglice ili pospanosti, kada se uzima antihipertenzivna terapija poput Telmisartan Teva Pharma.
- if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. 
- ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren..
Pharma. 
Teva Pharma.
Aluminium-Aluminium blisters : pack sizes of 28 tablets 
Aluminij-Aluminij blisteri: veličine pakiranja od 28 tableta.
Tablet 
tableta.
Teva Pharma Belgium N.V./S.A. 
Luxembourg/Luxemburg Teva Pharma Belgium S.A. Belgien/Belgique
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan Teva 
Ako se nešto od prethodno navedenog odnosi na Vas, obavijestite liječnika ili ljekarnika prije početka uzimanja Telmisartan Teva Pharma.
These pharmacologically mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation. 
Ove farmakološki posredovane nuspojave, poznate iz pretkliničkih ispitivanja s inhibitorima angiotenzin konvertirajućeg enzima i antagonistima receptora angiotenzina II, bile su spriječene oralnim nadomjeskom soli.
Read the package leaflet for further information 
Pročitajte uputu o lijeku za dodatne informacije.
Telmisartan Teva Pharma 20 mg tablets Telmisartan Teva Pharma 40 mg tablets Telmisartan Teva Pharma 80 mg tablets 
Telmisartan Teva Pharma 20 mg tablete Telmisartan Teva Pharma 40 mg tablete Telmisartan Teva Pharma 80 mg tablete
If you suffer from a condition called “orthostatic hypotension” (a drop in blood pressure on standing up from a sitting or lying position resulting in dizziness or faintness) your condition may worsen if you take Telmisartan Teva Pharma in combination with: 
Ako patite od stanja koje se naziva “ortostatska hipotenzija” (pad krvnog tlaka, tijekom ustajanja iz sjedećeg ili ležećeg položaja, koji dovodi do omaglice ili nesvjestice)
At the beginning of the preventive therapy with Telmisartan Teva Pharma 80 mg, blood pressure should be frequently monitored. 
Na početku preventivnog liječenja s Telmisartan Teva Pharmom od 80 mg, krvni tlak treba redovito pratiti.
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). 
Poznato je da izloženost antagonistima receptora angiotenzina II tijekom drugog i trećeg tromjesečja inducira fetotoksičnost u ljudi (smanjenje funkcije bubrega, oligohidramnij, usporena osifikacija kostiju lubanje) i neonatalnu toksičnost (zatajenje bubrega, hipotenzija, hiperkalijemija) (vidjeti dio 5.3.).
Contains sorbitol (E420). 
3. POPIS POMOĆNIH TVARI Sadrži sorbitol (E420).
Sepsis including fatal outcome1 
Sepsa uključujući smrtni ishod
At the beginning of the preventive therapy with Telmisartan Teva 80 mg, blood pressure should be frequently monitored. 
Na početku preventivnog liječenja s Telmisartanom Teva Pharma od 80 mg, krvni tlak treba redovito pratiti.
What you need to know before you take Telmisartan Teva Pharma Do not take Telmisartan Teva Pharma 
Što morate znati prije nego počnete uzimati Telmisartan Teva Pharma
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of blisters 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija za blistere
Telmisartan Teva Pharma is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Telmisartan Teva Pharma se ne preporučuje u ranoj trudnoći i ne smije se uzimati ako ste trudni dulje od 3 mjeseca, jer može izazvati teška oštećenja Vašeg djeteta ako se primjenjuje u ovom stadiju (vidjeti dio o trudnoći).
Some side effects can be serious and need immediate medical attention: 
Neke nuspojave mogu biti ozbiljne i zahtjevaju hitnu liječničku skrb: Ako Vam se pojave bilo koji od sljedećih simptoma, trebate odmah posjetiti svog liječnika:
Digoxin 
• Digoksin
The use of Telmisartan Teva Pharma in children and adolescents up to the age of 18 years is not recommended. 
Djeca i adolescenti Primjena Telmisartana Teva Pharma u djece i adolescenata do dobi od 18 godina se ne preporučuje.